TY - JOUR T1 - Mobility data can explain the entire COVID-19 outbreak course in Japan JF - medRxiv DO - 10.1101/2020.04.26.20081315 SP - 2020.04.26.20081315 AU - Junko Kurita AU - Tamie Sugawara AU - Yasushi Ohkusa Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/06/08/2020.04.26.20081315.abstract N2 - Background In Japan, as a countermeasure against the COVID-19 outbreak, voluntary restrictions against going out (VRG) have been applied.Object We examined mobility information provided by Apple Inc. to a susceptible–infected–recovery model.Method When applying a polynomial function to daily Apple data with the SIR model, we presumed the function up to a cubic term as in our earlier study.Results Estimation results demonstrated R0 as 1.507 and its 95% confidence interval was [1.502, 1.509].. The estimated coefficients of Apple data was 1.748 and its 95% confidence interval was [1.731, 1.788].Discussion and Conclusion Results show that mobility data from Apple Inc. can explain the entire course of the outbreak in COVID-19 in Japan. Therefore, monitoring Apple data might be sufficient to adjust control measures to maintain an effective reproduction number of less than one.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe author(s) received no specific funding for this work.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All information used for this study has been published. There is therefore no ethical issue related to this study.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yes1.Japan Ministry of Health, Labour and Welfare. Press Releases. 2.Apple. Mobility trend Data. https://www.mhlw.go.jp/stf/newpage_10723.html https://www.apple.com/covid19/mobility ER -